Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Günter Fingerle-Rowson

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Cell Division|July 21, 2007
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse modelsGünter Fingerle-Rowson, Oleksi Petrenko
Expert Opinion on Investigational Drugs|August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumabChristian Klein, Marina Bacac, Pablo Umana, et al.
Advances in Therapy|December 23, 2016
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell MalignanciesKensei Tobinai, Christian Klein, Naoko Oya, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2007
Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycleAlice Nemajerova, Ute M Moll, Oleksi Petrenko, et al.
International Journal of Cell Biology|September 14, 2012
Brain miffed by macrophage migration inhibitory factorNic E Savaskan, Günter Fingerle-Rowson, Michael Buchfelder, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2015
Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAENiannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, et al.
Archivum Immunologiae Et Therapiae Experimentalis|December 4, 2004
Macrophage migration inhibitory factor and its role in autoimmune diseasesClaudia M Denkinger, Christine Metz, Günter Fingerle-Rowson, et al.
British Journal of Clinical Pharmacology|May 4, 2019
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III studyEkaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, et al.
Rheumatology International|March 19, 2013
Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritisAnjana Singh, Lin Leng, Juan Fan, et al.
The Journal of Experimental Medicine|January 25, 2012
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progressionRamona Schulz, Natalia D Marchenko, Lena Holembowski, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Cell Division|July 21, 2007
MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse modelsGünter Fingerle-Rowson, Oleksi Petrenko
Expert Opinion on Investigational Drugs|August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumabChristian Klein, Marina Bacac, Pablo Umana, et al.
Advances in Therapy|December 23, 2016
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell MalignanciesKensei Tobinai, Christian Klein, Naoko Oya, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2007
Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycleAlice Nemajerova, Ute M Moll, Oleksi Petrenko, et al.
International Journal of Cell Biology|September 14, 2012
Brain miffed by macrophage migration inhibitory factorNic E Savaskan, Günter Fingerle-Rowson, Michael Buchfelder, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2015
Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAENiannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, et al.
Archivum Immunologiae Et Therapiae Experimentalis|December 4, 2004
Macrophage migration inhibitory factor and its role in autoimmune diseasesClaudia M Denkinger, Christine Metz, Günter Fingerle-Rowson, et al.
British Journal of Clinical Pharmacology|May 4, 2019
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III studyEkaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, et al.
Rheumatology International|March 19, 2013
Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritisAnjana Singh, Lin Leng, Juan Fan, et al.
The Journal of Experimental Medicine|January 25, 2012
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progressionRamona Schulz, Natalia D Marchenko, Lena Holembowski, et al.
Pageof 6